Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/52627
Title: Vaccine potential of recombinant cathepsin B against Fasciola gigantica
Authors: Pathanin Chantree
Manussabhorn Phatsara
Krai Meemon
Pannigan Chaichanasak
Narin Changklungmoa
Pornanan Kueakhai
Natcha Lorsuwannarat
Kant Sangpairoj
Sineenart Songkoomkrong
Chaitip Wanichanon
Tadashi Itagaki
Prasert Sobhon
Keywords: Immunology and Microbiology
Issue Date: 1-Sep-2013
Abstract: In Fasciola gigantica, cathepsin Bs, especially cathepsin B2 and B3 are expressed in early juvenile stages, and are proposed to mediate the invasion of host tissues. Thus they are thought to be the target vaccine candidates that can block the invasion and migration of the juvenile parasite. To evaluate their vaccine potential, the recombinant cathepsin B2 (rFgCatB2) and cathepsin B3 (rFgCatB3) were expressed in yeast, Pichia pastoris, and used to immunize mice in combination with Freund's adjuvant to evaluate the protection against the infection by F. gigantica metacercariae, and the induction of immune responses. Mice immunized with both recombinant proteins exhibited high percent of parasite reduction at 60% for rFgCatB2 and 66% for rFgCatB3. Immunization by both antigens induced continuously increasing levels of IgG1 and IgG2a with a higher level of IgG1 isotype, indicating the mixed Th1/Th2 responses with Th2 predominating. When examined individually, the higher levels of IgG1 and IgG2a were correlated with the lower numbers of worm recoveries. Thus, both cathepsin B2 and cathepsin B3 are plausible vaccine candidates whose potential should be further tested in large economic animals. © 2013 Elsevier Inc.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84880422630&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/52627
ISSN: 10902449
00144894
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.